| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Apoptosis-stimulating of p53 protein 2;Bcl2-binding protein;Bbp;Renal carcinoma antigen NY-REN-51;Tumor suppressor p53-binding protein 2;53BP2;p53-binding protein 2;p53BP2;TP53BP2;ASPP2, BBP; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Gene ID | |
| Host | |
| Immunogen | A synthesized peptide derived from human ASPP2 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-TP53BP2 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AOEA-20; isotype Rabbit IgG; reactivity: Human. Reported application contexts include WB, IHC, ICC, IF (as provided in the source record). Boster Bio Anti-ASPP2 Rabbit Monoclonal Antibody catalog # M02609. Tested in WB, IHC, ICC/IF applications. This antibody reacts with Human.
Key elements and design rationale
- Target: TP53BP2 (Apoptosis-stimulating of p53 protein 2).
- Antibody format: Monoclonal; clone AOEA-20; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
TP53BP2 (protein: T-cell surface glycoprotein CD3 zeta chain) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Regulator that plays a central role in regulation of apoptosis and cell growth via its interactions. Regulates TP53 by enhancing the DNA binding and transactivation function of TP53 on the promoters of proapoptotic genes in vivo. Inhibits the ability of APPBP1 to conjugate NEDD8 to CUL1, and thereby decreases APPBP1 ability to induce apoptosis. Impedes cell cycle progression at G2/M. Its apoptosis-stimulating activity is inhibited by its interaction with DDX42. . Reported cellular localization context: Cytoplasm, perinuclear region. Nucleus. Predominantly found in the perinuclear region. Some small fraction is nuclear. Sequester in the cytoplasm on overexpression of DDX42. Tissue expression notes (as provided): Widely expressed. Expressed in spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocyte. Reduced expression in breast carcinomas expressing a wild-type TP53 protein. Overexpressed in lung cancer cell lines. .
Research relevance and current trends
- Research context keywords from the source record include: Cell Biology,Cell Cycle,Cell Cycle Inhibitors.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
- Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
Workflow ideas (metafield): Validate TP53BP2 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect TP53BP2 expression by Western blot in cell or tissue lysates, Detect TP53BP2 in FFPE tissue sections by immunohistochemistry, Localize TP53BP2 by immunofluorescence/immunocytochemistry in cultured cells
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 45 kDa; calculated MW: 125616 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 45 kDa
- Cellular localization (provided): Cytoplasm, perinuclear region. Nucleus. Predominantly found in the perinuclear region. Some small fraction is nuclear. Sequester in the cytoplasm on overexpression of DDX42.
- Tissue details (provided): Widely expressed. Expressed in spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocyte. Reduced expression in breast carcinomas expressing a wild-type TP53 protein. Overexpressed in lung cancer cell lines. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
